FDA Panel Endorses Synergo Combo Product For Bladder Cancer
This article was originally published in The Gray Sheet
Executive Summary
Medical Enterprises' Synergo combination product for prevention of bladder cancer recurrence should be approved by FDA, contingent upon a one-year post-approval study to further assess its safety in the U.S. population, according to the agency's Gastroenterology and Urology Devices Panel
You may also be interested in...
Endo Pharmaceuticals Buys HealthTronics, Bringing Devices Into Urology Biz
In a push to diversify, Endo Pharmaceuticals announced May 5 that it is buying HealthTronics, a urology device and services company, for $223 million in cash, or $4.85 a share, plus an assumption of $35 million in debt
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.